PTO/SB/21 (01-03)

Under the Paper of Resection Act of 1995.	U.S. Patent	Approved for use through 04/30/2003. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE					
Under the Paper Add Reduction Act of 1995.	Application Number	n of information unless it displays a valid OMB control number. 10/666,594					
TRANSMITTAL	Filing Date	September 18, 2003					
FORM	First Named Inventor	Jolidon et al.					
(to be used for all correspondence after initial fo	Art Unit						
	Examiner Name						
Total Number of Pages in This Submission	Attorney Docket Number	21326 US					
· · · · · · · · · · · · · · · · · · ·	ENCLOSURES (Check all that	apply)					
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks References B1 to B4 and C1 to C17	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):					
SIGNAT	TURE OF APPLICANT, ATTORNI	EY, OR AGENT					
Firm or Individual Signature Date Kimberly J. Prior Kimberly J. Prior December 3, 2003	Dr.						
CE	RTIFICATE OF TRANSMISSION	MAILING					
	ansmitted to the USPTO or deposited with the Un	ited States Postal Service with sufficient postage as first class					
Typed or printed Kimberly !! Prior							
Signature Simple	Mes	Date December 3, 2003					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



極幹色 UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors:

Jolidon, et al.

Serial No. 10/666,594, filed September 18, 2003

(Ref. No. 21326 US)

For: 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 December 3, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1 to B4, and C1 to C17 listed on Form PTO-1449 are enclosed.

Document B1, which is not written in the English language, is abstracted in Document C17.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/666,594

Filed: September 18, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted.

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

Attachments

136561

			Cubationto	for f	orm 1440 A /DTO		_					
	Substitute for form 1449A/PTO					L	Complete if Known					
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number 10		0/666,594					
;				Filing Date Se		Septe	eptember 18, 2003					
		(Use sev	eral she	ets i	if necessary)		I	First Name Inventor	Jolido	on,	et al.	
Sheet	1		of	1			1	Attorney Docket Number	2132	261	US	
Sheet						U.S. PA	TE	NT DOCUMENTS			,	
Heamin Julials'	ner ,	Cite No.	Numb		Patent Doc	ument Kind Cod (if known)	-	Name of Patentee or Appl Cited Document	icant of	f	Date of Publication Cited document MM-DD-YY	nt
		A							3			
					F	OREIGN	PA	TENT DOCUMENTS				
Examin Initials'		Cite No. ¹	Foreig		Patent Docu Number	Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Documen		C	e of Publication of lited Document IM-DD-YYYY	T°
		B1	EP (9	85 665	U_{\perp}	D	egussa AG	()3/:	15/2000	
		B2	WO	97	7/33572	572 V S		Somerset		09/18/1997		
							P	harmaceuticals, Inc.				
		B3	WO	01	1/34172	V	V	ela Pharmaceuticals In	c. C)5/:	17/2001	
		B4	WO	96	5/40095		Н	arris, Richard, Y.	1	2/	19/1996	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
···	C1_	Bach, A. W. J., et al. Proc. Natl. Acad. Sci. USA 85:4934-4938 (1988)	
	C2	Cesura, A. M., & Pletscher, A., Prog. Drug Research 38:171-297 (1992)	
	C3	Fowler, C. J., et al. J. Neural. Transm. 49:1-20 (1980)	
	C4	Benedetti, M. S., et al. Biochem. Pharmacol. 38:555-561 (1989)	
	C5	Saura, J., et al. Neuroscience 70:755-774 (1996)	
	C6	Bentué-Ferrer, D., et al. CNS Drugs 6(3): 217-236 (1996)	
	C 7	Gardner, D. M., et al. J. Clin. Psychiatry 57(3):99-104 (1996)	
	C8	Ikuta, H., et al. J. Med. Chem. 30:1995-1998 (1987)	
	C9	Danishefsky, S., et al. J. Amer. Chem. Soc. 97:3239-3241 (1975)	
	C10	Lam, P. Y. S., et al. Tetrahedron Lett. 43:3091-3094 (2002)	
	C11	Lam, P. Y. S., et al. Synlett 5:674-676 (2000)	
	C12	Chan, D. M. T., et al. Tetrahedron Lett. 39:2933-2936 (1998)	
	C13	Wolfe, J. P., et al. J. Amer. Chem. Soc. 118:7215-7216 (1996)	
	C14	Freidinger, R. M., et al. J. Org. Chem. 47:104-109 (1982)	
	C15	Schlaeger, E. J., & Christensen, K., Cytotechnology 30:71-83 (1999)	
	C16	Zhou, M., & Panchuk-Voloshina, N., Analytical Biochemistry 253:169-	
		174 (1997)	
	C17	Abstract Corresponding to EP 0 985 665	
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant is to place a check mark here if English language Translation or abstract is attached.